Grifols SA (GRFS) Earnings Date & Reports

Key Takeaways

• Grifols reported third-quarter 2026 revenue of EUR 2,040 million, up 8.4% year over year on a constant-currency basis, led by its Biopharma business.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 9.8% to EUR 538 million, with the margin expanding 60 basis points to 26.4%.
• Net profit climbed 27.9% to EUR 162 million, bringing nine-month profit to EUR 390 million, up 28.4% year over year.
• Free cash flow before M&A (mergers and acquisitions) reached EUR 208 million in the quarter, lifting nine-month free cash flow to EUR 298 million, up 59%.
• Net leverage fell below 4.0x to 3.98x, down from 4.2x a year earlier, while liquidity increased to EUR 2,140 million.
• For more detail on the company's key developments, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• To discover AI-driven trading ideas across the broader market, explore Trending AI Robots.

Earnings Context and Why It Matters

Grifols is a Barcelona-based global healthcare company and one of the world's leading producers of plasma-derived medicines. Its results offer a read on underlying demand for immunoglobulin (IG) therapies, which treat immune deficiencies and neurological conditions. The Q3 2026 report arrives as the company executes its Value Creation Plan, a multi-year effort centered on deleveraging, cash-flow generation, and margin recovery. Investors are watching closely because Grifols has been steadily reducing leverage from a peak of 5.5x in mid-2024. Continued weakness in the Chinese albumin market and the dissolution of its QuidelOrtho diagnostics joint business have weighed on segments, making Biopharma momentum and balance-sheet progress the central themes of this quarter's update.

Reported Results

Grifols reported third-quarter 2026 revenue of EUR 2,040 million, an increase of 8.4% at constant currency, driven by 10.3% growth in Biopharma. Adjusted EBITDA reached EUR 538 million, up 9.8%, with the margin expanding to 26.4%. For the first nine months of 2026, revenue totaled EUR 5,614 million (up 4.6%) and adjusted EBITDA reached EUR 1,392 million (up 5.0%), with a 24.8% margin, roughly 30 basis points higher than a year earlier.

Net profit rose 27.9% to EUR 162 million in the quarter. Free cash flow before M&A reached EUR 208 million, bringing nine-month free cash flow to EUR 298 million, EUR 110 million higher than the prior-year period. Net leverage declined to 3.98x from 4.2x a year earlier, and liquidity stood at EUR 2,140 million. The board approved an interim dividend of EUR 0.15 per share, payable in early December 2026.

By franchise, immunoglobulin revenue grew 11.3% at constant currency in the quarter, with subcutaneous IG up 40.3%. Alpha-1 and specialty proteins rose 18.2%, while albumin declined 13.2% amid continued pricing and inventory pressures in China. Diagnostics revenue fell on the QuidelOrtho joint-business dissolution.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Grifols or exploring the broader healthcare sector, the AI Screener can help surface actionable ideas faster.

Market Reaction and Investor Sentiment

Shares of Grifols moved higher following the release, reflecting a broadly positive reception to margin expansion, stronger free cash flow, and the decline in leverage below 4.0x. Investors appeared to weigh the strength of the immunoglobulin franchise and improving profitability against ongoing softness in the Chinese albumin market and the Diagnostics decline tied to the QuidelOrtho joint-business dissolution. Management reiterated its full-year 2026 guidance, including an adjusted EBITDA margin target of 25%, which reinforced confidence in the outlook. The combination of accelerating Biopharma growth, a recovering balance sheet, and a reinstated interim dividend contributed to constructive sentiment even as segment-level headwinds persisted.

Forward Outlook and Key Factors to Monitor

Looking ahead, Grifols reaffirmed its 2026 targets, including a full-year adjusted EBITDA margin of 25% and continued free cash flow growth. Management also flagged that Q4 2026 Biopharma growth may moderate as the company laps a strong prior-year sales quarter, and that some free cash flow conversion benefits in the third quarter may unwind in the fourth.

Several factors will shape the coming quarters. First, the trajectory of the immunoglobulin franchise remains the single most important driver, with subcutaneous IG continuing to grow rapidly. Second, the Chinese albumin market will be a key swing factor, as prescribing restrictions, elevated channel inventories, and pricing pressure have weighed on that franchise for multiple quarters.

Third, investors should monitor the ramp-up of Grifols Egypt, which is targeting roughly one million liters of plasma collection in 2026, as a longer-term supply-security initiative. Finally, the balance sheet remains in focus. With no significant debt maturities until the fourth quarter of 2028 following recent refinancing, attention will shift to whether Grifols can sustain its deleveraging trajectory while balancing shareholder returns such as the newly announced interim dividend.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations